Your browser doesn't support javascript.
loading
Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.
Arshad, Usman; Pertinez, Henry; Box, Helen; Tatham, Lee; Rajoli, Rajith K R; Curley, Paul; Neary, Megan; Sharp, Joanne; Liptrott, Neill J; Valentijn, Anthony; David, Christopher; Rannard, Steve P; O'Neill, Paul M; Aljayyoussi, Ghaith; Pennington, Shaun H; Ward, Stephen A; Hill, Andrew; Back, David J; Khoo, Saye H; Bray, Patrick G; Biagini, Giancarlo A; Owen, Andrew.
Affiliation
  • Arshad U; Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
  • Pertinez H; Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
  • Box H; Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
  • Tatham L; Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
  • Rajoli RKR; Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
  • Curley P; Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
  • Neary M; Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
  • Sharp J; Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
  • Liptrott NJ; Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
  • Valentijn A; Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
  • David C; Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
  • Rannard SP; Department of Chemistry, University of Liverpool, Liverpool, UK.
  • O'Neill PM; Department of Chemistry, University of Liverpool, Liverpool, UK.
  • Aljayyoussi G; Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Centre for Drugs and Diagnostics, Liverpool, UK.
  • Pennington SH; Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Centre for Drugs and Diagnostics, Liverpool, UK.
  • Ward SA; Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Centre for Drugs and Diagnostics, Liverpool, UK.
  • Hill A; Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
  • Back DJ; Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
  • Khoo SH; Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
  • Bray PG; Pat Bray Electrical, Wigan, UK.
  • Biagini GA; Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Centre for Drugs and Diagnostics, Liverpool, UK.
  • Owen A; Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
Clin Pharmacol Ther ; 108(4): 775-790, 2020 10.
Article de En | MEDLINE | ID: mdl-32438446

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Antiviraux / Pneumopathie virale / Systèmes de délivrance de médicaments / Infections à coronavirus / Repositionnement des médicaments / Betacoronavirus Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Clin Pharmacol Ther Année: 2020 Type de document: Article Pays d'affiliation: Royaume-Uni Pays de publication: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Antiviraux / Pneumopathie virale / Systèmes de délivrance de médicaments / Infections à coronavirus / Repositionnement des médicaments / Betacoronavirus Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Clin Pharmacol Ther Année: 2020 Type de document: Article Pays d'affiliation: Royaume-Uni Pays de publication: États-Unis d'Amérique